Last reviewed · How we verify
mesenchymal stem cell-derived exosomes
mesenchymal stem cell-derived exosomes is a Small molecule drug developed by First Affiliated Hospital of Guangxi Medical University. It is currently FDA-approved. Also known as: MSC-Exos, Fetal stem cell exosomes.
At a glance
| Generic name | mesenchymal stem cell-derived exosomes |
|---|---|
| Also known as | MSC-Exos, Fetal stem cell exosomes |
| Sponsor | First Affiliated Hospital of Guangxi Medical University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Exosomes Effect on Visual Function in CVI
- Safety and Feasibility of Nasal Delivery of Human Dental Follicle Mesenchymal Stem Cell-Derived Exosomes for Negative Symptoms in Treatment-Resistant Schizophrenia: A Pilot Study (EARLY_PHASE1)
- Mesenchymal Stem Cell and Exosome Therapy for Diabetic Erectile Dysfunction (PHASE2, PHASE3)
- Evaluation of Neuroinduced Mesenchymal Stem Cells and Mesenchymal Stem Cell-Derived Exosomes in Patients With Parkinsonism (PHASE2)
- Objective Evaluation of Intradermal MSC-Derived Exosome Therapy on Facial Skin Quality (PHASE3)
- Evaluation of the Safety and Preliminary Efficacy of Neuroinduced Mesenchymal Stem Cells and Exosome Therapy in Patients With Spinocerebellar Palsy (PHASE1, PHASE2)
- The Effect of CB-Exo-A600 in Mild to Moderate Alzheimer's Disease (PHASE1, PHASE2)
- Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- mesenchymal stem cell-derived exosomes CI brief — competitive landscape report
- mesenchymal stem cell-derived exosomes updates RSS · CI watch RSS
- First Affiliated Hospital of Guangxi Medical University portfolio CI
Frequently asked questions about mesenchymal stem cell-derived exosomes
What is mesenchymal stem cell-derived exosomes?
mesenchymal stem cell-derived exosomes is a Small molecule drug developed by First Affiliated Hospital of Guangxi Medical University.
Who makes mesenchymal stem cell-derived exosomes?
mesenchymal stem cell-derived exosomes is developed and marketed by First Affiliated Hospital of Guangxi Medical University (see full First Affiliated Hospital of Guangxi Medical University pipeline at /company/first-affiliated-hospital-of-guangxi-medical-university).
Is mesenchymal stem cell-derived exosomes also known as anything else?
mesenchymal stem cell-derived exosomes is also known as MSC-Exos, Fetal stem cell exosomes.
What development phase is mesenchymal stem cell-derived exosomes in?
mesenchymal stem cell-derived exosomes is FDA-approved (marketed).
Related
- Manufacturer: First Affiliated Hospital of Guangxi Medical University — full pipeline
- Also known as: MSC-Exos, Fetal stem cell exosomes
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing